Skip to main
IMTX

Immatics NV (IMTX) Stock Forecast & Price Target

Immatics NV (IMTX) Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 80%
Buy 20%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Immatics is well-positioned for success due to its strong financial position with $505.8 million in cash, providing operational runway until 2H27, and its promising pipeline of T-cell redirecting immunotherapies for the treatment of various cancers. Despite clinical risks and regulatory unknowns, the company's potential for global sales of €573.7 million by 2035E and a 25% PoS for IMA402 in melanoma and ovarian cancer support a BUY rating with a PT of $19/share.

Bears say

Immatics is heavily dependent on its clinical pipeline, which may not be as strong as initially thought. The company also faces significant competition from other players in the T-cell therapy space, as well as potential competition from other modalities. Additionally, the company may need to raise additional capital before reaching profitability, which could result in share dilution for shareholders.

Immatics NV (IMTX) has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 80% of analysts recommend a Strong Buy, 20% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Immatics NV and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Immatics NV (IMTX) Forecast

Analysts have given Immatics NV (IMTX) a Strong Buy based on their latest research and market trends.

According to 5 analysts, Immatics NV (IMTX) has a Strong Buy consensus rating as of May 5, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $19, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $19, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Immatics NV (IMTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.